Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 06, 2024 16:05 ET
|
Caribou Biosciences, Inc.
-- Advancing four clinical-stage programs for hematologic malignancies and autoimmune diseases; multiple clinical data reports planned for 2025 -- -- Enrolling patients with LBCL (2L and after prior...
RiskLayer announces its Builders Round led by Antler for building a DeFi Security Middleware on EigenLayer
July 25, 2024 07:11 ET
|
Chainrisk Labs
RiskLayer, developed by Chainrisk Labs, has secured its Builders Round, co-led by Antler and Momentum6. This round includes investors like Wagmi Ventures,
Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024 10:00 ET
|
Caribou Biosciences, Inc.
BERKELEY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts...
Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024
January 07, 2024 11:00 ET
|
Caribou Biosciences, Inc.
-- Tim Kelly to lead Caribou’s technical operations strategy and execution -- -- CB-010 ANTLER Phase 1 trial initial dose expansion data and RP2D to be disclosed Q2 2024; Caribou plans to initiate...
Caribou Biosciences Reports Positive Clinical Data from Dose Escalation of CB-010 ANTLER Phase 1 Trial in r/r B-NHL
July 13, 2023 16:01 ET
|
Caribou Biosciences, Inc.
-- CB-010 allogeneic CAR-T cell therapy data rival response rates and safety profile of approved autologous CAR-T cell therapies -- -- 94% overall response rate (ORR), 69% complete response (CR)...
Caribou Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 09, 2023 16:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023 -- -- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients...
Caribou Biosciences Announces Appointment of Stephen J. Schuster, MD, to its Scientific Advisory Board
May 08, 2023 09:00 ET
|
Caribou Biosciences, Inc.
-- Dr. Schuster is a world-renowned hematologist and pioneer in CAR-T cell therapy development -- BERKELEY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a...
Caribou Biosciences Initiates Dose Expansion Portion of CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients
March 29, 2023 08:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 is the first allogeneic CAR-T cell therapy, to Caribou’s knowledge, to be evaluated clinically in second-line LBCL patients -- -- Next ANTLER update planned for H2 2023 -- BERKELEY,...
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
November 08, 2022 16:00 ET
|
Caribou Biosciences, Inc.
-- CB-010 ANTLER Phase 1 trial in r/r B-NHL advancing; additional data from cohort 1 expected by YE 2022 -- -- CB-011 IND application for r/r MM submitted to FDA in Q4 2022 -- -- Strong...